Fortis Healthcare Ltd Q2 FY26: ₹2,331 Cr Revenue, ₹329 Cr Profit, 24% OPM — Hospitals Now Doing Better Margins Than Some FMCG Brands
1. At a Glance
Some hospitals cure patients; others cure balance sheets. Fortis Healthcare Ltd, the ₹70,792 crore healthcare behemoth, has just pulled off a quarter where operating margins hit 24% — almost as if doctors in white coats suddenly found MBA degrees. The Q2 FY26 consolidated revenue stands at ₹2,331 crore, up 17.2% YoY, while net profit surged 40.2% to ₹329 crore. Stock price? ₹938, trading at a cool 70× earnings, which means Fortis is now priced like a premium Botox session.
With a network of 36 healthcare facilities and ~4,000 operational beds, Fortis sits comfortably between spiritual healing and capitalist resurrection. The Bhagavad Gita once said, “Karmanye vadhikaraste, ma phaleshu kadachana.” Clearly, someone at Fortis read that — because their karma (operations) are producing some divine phal (profits).
ROE at 10.1% and ROCE at 12% show there’s room for more oxygen in the profitability ward. The company has raised ₹1,550 crore via NCDs for diagnostics expansion, which is fancy talk for “let’s buy some more labs and robots before Apollo beats us to it.”
2. Introduction
There was a time when hospital bills were scarier than the illness. But Fortis seems to have cured that fear — for investors, at least. From financial ventilator in 2018 under the Singh brothers’ chaos to surgical precision under IHH Healthcare Berhad’s stewardship, Fortis has evolved into the benchmark of private hospital professionalism.
In the healthcare Olympics of India, Apollo may be the Usain Bolt, but Fortis has quietly become the marathon runner who keeps getting stronger after every kilometer. Q2 FY26 results show a business that’s finally found its rhythm — solid occupancy at 69%, ARPOB (Average Revenue Per Occupied Bed) touching ₹59,870 per day, and digital revenue contributing a surprising 30%. That’s right — Fortis is now as online as your favorite food delivery app, except the delivery is MRI scans and not momos.
This is the story of a hospital chain that has turned from a courtroom regular into a corporate miracle. The Singh brothers’ ghosts have been exorcised, IHH’s open offer is complete, and Fortis now plans to expand its bed count to 6,000 by FY28. Imagine — more beds, more patients, more profits.
So let’s dissect Fortis Healthcare, scalpel in one hand, sarcasm in the other.
3. Business Model – WTF Do They Even Do?
Fortis Healthcare runs hospitals, day-care centers, and diagnostics labs across India, Nepal, Sri Lanka, and Dubai. Think of it as the “Big Bazaar of healthcare,” only with more MRI machines and fewer shopping carts.
The hospital segment remains its heart and lungs — 27 multi- and super-specialty hospitals, staffed by over 6,850 doctors and 6,600 nurses. These facilities handle cardiac sciences, oncology, orthopedics, neurosciences, and about everything that hurts, clicks, or beats abnormally.
Then comes the diagnostics segment, run through its subsidiary Agilus Diagnostics (formerly SRL), where Fortis holds an 89.2% stake. With 405 labs and 4,126 touchpoints, this business processes millions of blood samples that most of us would rather not see.
Revenue split? Hospitals account for the majority, but diagnostics is the rising star, contributing ~15–20% of revenues. Fortis’ ₹1,550 crore NCD fund raise in Dec 2024 was used to increase its diagnostics stake — which basically means it decided to own more of its “cash test cow.”
So yes, Fortis heals the body but fattens the bottom line — one test at a time.
Now that’s some premium valuation — higher than most healthy lungs’ oxygen saturation. But hey, the market loves a recovery story with clean governance and compounding margins.
5. Valuation Discussion – Fair Value Range Only
Method 1: P/E Approach
Industry P/E: 53.7 Fortis EPS (annualized): ₹17.04 Fair value range = ₹17.04 × (55 to 65) = ₹938 – ₹1,107
Assume 10% revenue CAGR next 5 years, 20% OPM, discount 10%. Fair Value ≈ ₹850–₹1,000/share
✅ Fair Value Range (Educational Only): ₹575 – ₹1,100/share
This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Fortis’ latest saga reads like a Netflix medical drama — expansion announcements, Supreme Court clean-ups, and IHH finally completing its open offer in Nov 2025. After years of litigation limbo, SEBI approved the IHH open offer for 197 million shares (26.1%) at ₹170 plus ₹53.80 interest — effectively closing a six-year soap opera.
The company also received a litigation order in April 2024 reducing contingent liabilities by ₹124.37 crore, and
